Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
EyeBio logo — Developing a new generation of therapies to protect, restore...

EyeBio

Developing a new generation of therapies to protect, restore, and improve vision

Founded 2021 United Kingdom London, United Kingdom 109 employees Acquired Total: $3.13B Biotechnology

General Information

Company Name EyeBio
Founded Year 2021
Location United Kingdom London, United Kingdom
Founders / Decision Makers
Team member
Employees 109
Industries Biotechnology
Funding Stage Acquired
Business Model B2B
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with EyeBio. To contact EyeBio, visit eyebiotech.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does EyeBio compare?

A PDF of EyeBio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting EyeBio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About EyeBio

EyeBio, founded in 2021, is an innovative biotechnology company based in the United Kingdom, specializing in ophthalmology. The company's driving mission, encapsulated in its slogan—"Developing a new generation of therapies to protect, restore, and improve vision"—focuses on addressing the unmet needs of patients with sight-threatening eye diseases.

In a significant financial milestone, EyeBio recently secured a $3.00B acquisition investment from Merck in May 2024. This substantial investment underscores the confidence major industry players have in EyeBio's potential to revolutionize therapies in the eye care sector.

Operating within the Biotechnology industry, EyeBio is poised to leverage this funding to advance its pipeline of visionary therapies. The strategic investment by Merck also enhances EyeBio's capacity for innovation and its role as a leader in ophthalmological biotechnological advancements.

Business keywords: ophthalmology, biopharmaceuticals, vision therapy, eye diseases, age-related macular degeneration, anti-vascular endothelial growth factor, sight restoration, eye disorder prevention, vision improvement, regenerative medicine, drug development, therapeutics, vision protection, sight-threatening conditions

Services & Products

Research and Development
Therapeutic Modalities
Clinical Trials
Patient Support Programs
Business Development and Licensing
Philanthropy and Medical Outreach

Target Customers

Patients with Retinal Diseases Healthcare Professionals Research Scientists Pharmaceutical Distributors Investors Healthcare Institutions

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Acquisition $3.00B 1
Merck
Merck
01 May 2024
Series A $65.00M 7
SV Health Investors Jeito Capital Omega Funds
SV Health Investors, Jeito Capital +5
01 Nov 2023
Series A $65.00M 5
SV Health Investors Jeito Capital Merck
SV Health Investors, Jeito Capital +3
01 Feb 2022
Seed Undisclosed 1
SV Health Investors
SV Health Investors
01 Aug 2021

EyeBio Alternatives & Competitors

View All Alternatives
EyeBio vs
REGENXBIO
REGENXBIO United States

Seeking to improve lives through the curative potential of gene therapy.

IPO
389 employees
Biopharma, Biotechnology
Compare EyeBio vs REGENXBIO
EyeBio vs
PulseSight Therapeutics
PulseSight Therapeutics France

PulseSight is an ophthalmology drug development company developing disruptive non-viral gene therapi...

Seed
9 employees
Biotechnology, Health and Wellness
Compare EyeBio vs PulseSight Therapeutics
EyeBio vs
Complement Therapeutics
Complement Therapeutics Germany

Developing the next generation of complement medicines

Series A
36 employees
Biotechnology
Compare EyeBio vs Complement Therapeutics
Also compare with: EyeBio vs Restore Vision Restore Vision EyeBio vs 4D Molecular Therapeutics 4D Molecular Therapeutics View all alternatives

FAQ About EyeBio

Developing a new generation of therapies to protect, restore, and improve vision
EyeBio was founded in 2021.
EyeBio is headquartered in London, United Kingdom.
EyeBio operates in Biotechnology. Its work centres on ophthalmology, biopharmaceuticals, vision therapy and eye diseases. Its customers include Patients with Retinal Diseases, Healthcare Professionals and Research Scientists.
EyeBio has a B2B business model. Its revenue comes from Licensing and Product Sales.
EyeBio has approximately 109 employees.
EyeBio has completed 4 funding rounds, raising a total of $3.13B. The latest funding stage is Acquired.
EyeBio offers: Research and Development, Therapeutic Modalities, Clinical Trials, Patient Support Programs, Business Development and Licensing, Philanthropy and Medical Outreach.
Top alternatives and competitors to EyeBio include REGENXBIO, PulseSight Therapeutics, Complement Therapeutics, Vantage Biosciences, Calluna Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
EyeBio and REGENXBIO are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for EyeBio, https://bouncewatch.com/company/eyebiotech, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes